Phathom Maintains 2026 Net Revenue Forecast of $310 Million-$325 Million

Bitget2026/10/29 11:39

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Phathom Pharmaceuticals maintained its 2026 net revenue guidance of $310 million to $325 million.
Operating expense guidance remains $235 million to $245 million, excluding stock-based compensation; gross-to-net discounts are forecast at 55% to 59%.
Operating profitability is expected for the remainder of the year and the full year, excluding stock-based compensation.
Cash flow is expected to turn positive in 2027.
Third-quarter 2026 net revenue reached $84.7 million, up approximately 71% from a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Phathom Maintains 2026 Net Revenue Forecast of $310 Million-$325 Million

You may also like

Crypto prices